XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
XTL Biopharmaceuticals Ltd. has entered into a settlement agreement involving an adjustment of American Depositary Shares and warrants with its subsidiary, The Social Proxy Ltd. The resolution saw the return of over 372 million ordinary shares to XTL’s treasury. XTL continues to explore strategic collaborations in the Lupus treatment space while expanding its portfolio.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.
